Abstract
The SARS-Cov-2 pandemic has seen the challenge of controlling novel zoonotic diseases that have high infection fatality rates, including a natural capacity for the evolution of variants that transmit more easily and evade immunity. In dealing with current and future similar pandemics, the question arises: what is the optimum strategy to control infections. Although a complex question, a key neglected component to appraise the elimination strategy is simple theory predicting the expected timescales of elimination. We use simple random walk and branching process theory to provide new insights on the process of elimination using non-pharmaceutical interventions. Our central achievement is a full theory of the distribution of extinction times — which we find is an extreme value Gumbel distribution — for any value of the reproductive number including some degree of population immunity. Overall, for the original SARS-Cov-2 variant our results predict rapid extinction — of order months — of an epidemic or pandemic if the reproductive number is kept to Re < 0.5; in a counterfactual scenario with global adoption of an elimination strategy in June 2020, SARS-Cov-2 could have been eliminated world-wide by early January 2021. Looking to the future, our results would suggest that elimination using NPIs is a more optimal strategy to control — and potentially eradicate — a Sars-like pandemic, in its early stages before the evolution of variants with greater transmissibility.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.